 IntegraTM grafts received FDA approval in 1996 and since then are being applied worldwide to treat patients who are in need of new skin to treat massive burns, those undergoing plastic surgery of the skin, and patients with chronic skin wounds as well as others who suffer from certain forms of skin cancer.In clinical practice, a thin graft sheet manufactured from the active collagen scaffold is placed on the injury site, which is then covered with a thin sheet of silicone elastomer that protects the wound site from bacterial infection and dehydration.The graft can be seeded with autologous cells (keratinocytes) in order to accelerate wound closure, however the presence of these cells is not required for regenerating the dermis.